VIVUS Inc. (VVUS) announced that a New Jersey district court issues a Markman ruling favoring the company in a patent infringement litigation related to its Qsymia against potential generic competitors Actavis (AGN) and Teva Pharmaceutical Industries (TEVA). In a Markman ruling, also known as a claim construction ruling, the court determines the meaning of disputed patent claims at issue in the litigation. In this case, the judge adopted VIVUS' proposed constructions for nine of the 10 patents in dispute. A compromise construction was adopted for the remaining one. The last of VIVUS' patents expires in 2029.